Diagnostics startup Theranos has been wowing investors and healthcare observers with its goal to disrupt the blood-testing industry, but now its core technology and practices are being questioned.
News & Features
A report from McKinsey & Co. states that medtech companies can get substantial benefits if they can build credibility among hospital customers.
There are real, practical concerns regarding digital health that will need to be ironed out before adoption can take place, says a well regarded cardiologist .
Waiting to consider reimbursement until after your device has secured regulatory approval can be expensive and time-consuming.
Masimo CEO Joe Kiani believes if medtech companies share their data it would help to reduce preventable deaths but some companies are refusing.
A new survey of U.S. surgeons show that the demand for surgical robots is set to grow in the future.
St. Jude Medical cuts its revenue expectation for its novel congestive heart failure management device. Did a Medtronic executive have it right when he described CardioMEMS as an expensive solution?
FDA interest in involving public and private payers early in the review process may be very beneficial to medical device makers.
Although overall growth in emerging markets is slowing, Abbott Laboratories CEO Miles D. White remains upbeat about the prospects for healthcare companies in countries like China.
Stryker bought two companies in 2015 so far, compared with four last year, but the company's chief executive indicated that doing deals will be a priority.
Here's an example of how a startup is pursuing an outsourced product development strategy and reaping benefits
The blood-testing industry has been in the news a lot lately because of Theranos, but other companies are reimagining the industry as well.
Seventh Sense Biosystems Touch-Activated Phlebotomy Device Name: Seventh Sense Biosystems